Pharmacokinetics of benzodiazepine hypnotics

David J. Greenblatt, Marcia Divoll, Darrell R. Abernethy, Ann Locniskar, Richard I. Shader

Research output: Contribution to journalArticle

Abstract

Three benzodiazepine derivatives are currently indicated specifically for the treatment of insomnia in the United States. Flurazepam is biotransformed to at least two rapidly appearing and rapidly eliminated intermediate metabolites which probably contribute to sleep induction. The final metabolite, desalkylflurazepam, appears slowly, but has a long half-life ranging from 40 to 150 h. This metabolite accumulates extensively during multiple dosage. Temazepam is a slowly absorbed drug and has an intermediate half-life in the range of 10-20 h. Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating. Understanding of the pharmacokinetics of benzodiazepine hypnotics can contribute to understanding of their clinical properties.

Original languageEnglish (US)
Pages (from-to)70-75
Number of pages6
JournalPharmacology
Volume27
DOIs
StatePublished - 1983
Externally publishedYes

Fingerprint

Hypnotics and Sedatives
Benzodiazepines
Half-Life
Pharmacokinetics
Flurazepam
Triazolam
Temazepam
Sleep Initiation and Maintenance Disorders
Sleep
Pharmaceutical Preparations
Therapeutics

Keywords

  • Benzodiazepines
  • Flurazepam
  • Hypnotics
  • Pharmacokinetics
  • Temazepam
  • Triazolam

ASJC Scopus subject areas

  • Pharmacology

Cite this

Greenblatt, D. J., Divoll, M., Abernethy, D. R., Locniskar, A., & Shader, R. I. (1983). Pharmacokinetics of benzodiazepine hypnotics. Pharmacology, 27, 70-75. https://doi.org/10.1159/000137913

Pharmacokinetics of benzodiazepine hypnotics. / Greenblatt, David J.; Divoll, Marcia; Abernethy, Darrell R.; Locniskar, Ann; Shader, Richard I.

In: Pharmacology, Vol. 27, 1983, p. 70-75.

Research output: Contribution to journalArticle

Greenblatt, DJ, Divoll, M, Abernethy, DR, Locniskar, A & Shader, RI 1983, 'Pharmacokinetics of benzodiazepine hypnotics', Pharmacology, vol. 27, pp. 70-75. https://doi.org/10.1159/000137913
Greenblatt DJ, Divoll M, Abernethy DR, Locniskar A, Shader RI. Pharmacokinetics of benzodiazepine hypnotics. Pharmacology. 1983;27:70-75. https://doi.org/10.1159/000137913
Greenblatt, David J. ; Divoll, Marcia ; Abernethy, Darrell R. ; Locniskar, Ann ; Shader, Richard I. / Pharmacokinetics of benzodiazepine hypnotics. In: Pharmacology. 1983 ; Vol. 27. pp. 70-75.
@article{f60d4b8c47ce4fcbaf32d561f5ba4c1b,
title = "Pharmacokinetics of benzodiazepine hypnotics",
abstract = "Three benzodiazepine derivatives are currently indicated specifically for the treatment of insomnia in the United States. Flurazepam is biotransformed to at least two rapidly appearing and rapidly eliminated intermediate metabolites which probably contribute to sleep induction. The final metabolite, desalkylflurazepam, appears slowly, but has a long half-life ranging from 40 to 150 h. This metabolite accumulates extensively during multiple dosage. Temazepam is a slowly absorbed drug and has an intermediate half-life in the range of 10-20 h. Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating. Understanding of the pharmacokinetics of benzodiazepine hypnotics can contribute to understanding of their clinical properties.",
keywords = "Benzodiazepines, Flurazepam, Hypnotics, Pharmacokinetics, Temazepam, Triazolam",
author = "Greenblatt, {David J.} and Marcia Divoll and Abernethy, {Darrell R.} and Ann Locniskar and Shader, {Richard I.}",
year = "1983",
doi = "10.1159/000137913",
language = "English (US)",
volume = "27",
pages = "70--75",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Pharmacokinetics of benzodiazepine hypnotics

AU - Greenblatt, David J.

AU - Divoll, Marcia

AU - Abernethy, Darrell R.

AU - Locniskar, Ann

AU - Shader, Richard I.

PY - 1983

Y1 - 1983

N2 - Three benzodiazepine derivatives are currently indicated specifically for the treatment of insomnia in the United States. Flurazepam is biotransformed to at least two rapidly appearing and rapidly eliminated intermediate metabolites which probably contribute to sleep induction. The final metabolite, desalkylflurazepam, appears slowly, but has a long half-life ranging from 40 to 150 h. This metabolite accumulates extensively during multiple dosage. Temazepam is a slowly absorbed drug and has an intermediate half-life in the range of 10-20 h. Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating. Understanding of the pharmacokinetics of benzodiazepine hypnotics can contribute to understanding of their clinical properties.

AB - Three benzodiazepine derivatives are currently indicated specifically for the treatment of insomnia in the United States. Flurazepam is biotransformed to at least two rapidly appearing and rapidly eliminated intermediate metabolites which probably contribute to sleep induction. The final metabolite, desalkylflurazepam, appears slowly, but has a long half-life ranging from 40 to 150 h. This metabolite accumulates extensively during multiple dosage. Temazepam is a slowly absorbed drug and has an intermediate half-life in the range of 10-20 h. Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating. Understanding of the pharmacokinetics of benzodiazepine hypnotics can contribute to understanding of their clinical properties.

KW - Benzodiazepines

KW - Flurazepam

KW - Hypnotics

KW - Pharmacokinetics

KW - Temazepam

KW - Triazolam

UR - http://www.scopus.com/inward/record.url?scp=0021047258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021047258&partnerID=8YFLogxK

U2 - 10.1159/000137913

DO - 10.1159/000137913

M3 - Article

C2 - 6142469

AN - SCOPUS:0021047258

VL - 27

SP - 70

EP - 75

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

ER -